Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent
Open accessThe DOI matches its Crossref record; 208 of the 208 references it cites were found in a registry or an index.
Abstract
Inflammation contributes to many chronic conditions. It is often associated with circulating pro-inflammatory cytokines and immune cells. GLP-1 levels correlate with disease severity. They are often elevated and can serve as markers of inflammation. Previous studies have shown that oxytocin, hCG, ghrelin, alpha-MSH and ACTH have receptor-mediated anti-inflammatory properties that can rescue cells from damage and death. These peptides have been studied well in the past century. In contrast, GLP-1 and its anti-inflammatory properties have been recognized only recently. GLP-1 has been proven to be a useful adjuvant therapy in type-2 diabetes mellitus, metabolic syndrome, and hyperglycemia. It also lowers HbA1C and protects cells of the cardiovascular and nervous systems by reducing inflammation and apoptosis. In this review we have explored the link between GLP-1, inflammation, and sepsis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures












Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Additionally, GLP-1 mitigates liver inflammation and fibrosis by inhibiting the NF-κB pathway, reducing the release of pro-inflammatory cytokines such as TNF-α and IL-6, and thus suppressing inflammatory pathways.307,413”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [413]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“By modulating inflammatory responses, GLP-1RAs can help prevent the degeneration of dopamine-producing cells.413”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [413]
The cited source says what the claim attributes to it.
In the citing paper
“Treatment with liraglutide reduced NADPH oxidase activity, increased cAMP-PKA activity, and reduced mesangial expansion in mouse models.69,70”
From Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications (2024) · cites this paper as [69]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–208 of 208
Abnormal Circulating Levels of Matrix Metalloproteinases and their Inhibitors in Diabetes Mellitus
Zayani, Y., Elasmi, M., Jacob, M. P., Zidi, W., Ftouhi, B., Feki, M., Slimane, H., & Kaabachi, N. (2012) · Clinical Laboratory · doi:10.7754/clin.lab.2011.110904 · Cited by 15
Exenatide Once Weekly for Management of Type 2 Diabetes: A Review
Inaishi, J., & Saisho, Y. (2022) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s288846 · Cited by 15
Harkavyi, A., Rampersaud, N., & Whitton, P. S. (2013) · Journal of Neurodegenerative Diseases · doi:10.1155/2013/407152 · Cited by 14 · cited 1×
“The intraventricular administration of GLP-1 protects mice from MPTP-induced dopaminergic cell loss (64, 86, 108, 109).”
BackgroundYoo, S. K., Mehdi, S. F., Pusapati, S., Mathur, N., Anipindi, M., Lunenfeld, B., Lowell, B., Yang, H., Metz, C. N., Khan, S. A., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.714177 · Cited by 14
Self-citationWhiting, L., Stewart, K. W., Hay, D. L., Harris, P. W. R., Choong, Y. S., Phillips, A. R. J., Brimble, M. A., & Cooper, G. J. S. (2015) · Physiological Reports · doi:10.14814/phy2.12638 · Cited by 12
Central effects of glucagon-like peptide-1 on cold-restraint stress-induced gastric mucosal lesions.
Işbil-Büyükcoşkun, N., Güleç, G., Etöz, B. Ç., & Özlük, K. (2007) · The Turkish Journal of Gastroenterology · Cited by 9
Xu, L., & Ren, Y. (2019) · PubMed · Cited by 5
Wolak, M., Drobnik, J., & Bojanowska, E. (2021) · PubMed · doi:10.26402/jpp.2021.3.14 · Cited by 4
Research works printed but not linked: 1
- 44. Dungan K, DeSantis A. Glucagon-like peptide 1-based therapies for the treatment of type 2 diabetes mellitus. in: Uptodate. Post DN, (Ed.), UpToDate. Waltham, MA: UpToDateInc. Available at: https://www.uptodate.com/contents/glucagon-like-peptide- 1-based-therapies-for-the-treatment-of-type-2-diabetes-mellitus.
Cited by
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036
Mechanisms of long COVID and the path toward therapeutics
Peluso, M. J., & Deeks, S. G. (2024) · Cell · doi:10.1016/j.cell.2024.07.054 · Cited by 341
Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications
Alharbi, S. H. (2024) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188231222367 · Cited by 358
“69,70 Liraglutide has been shown to modulate immune responses in individuals with diabetes.”
BackgroundBrain-wide cell-type-specific transcriptomic signatures of healthy ageing in mice
Jin, K., Yao, Z., van Velthoven, C. T. J., Kaplan, E. S., Glattfelder, K. J., Barlow, S. T., Boyer, G., Carey, D., Casper, T., Chakka, A. B., et al. (2025) · Nature · doi:10.1038/s41586-024-08350-8 · Cited by 189
Unveiling Gestational Diabetes: An Overview of Pathophysiology and Management
Mittal, R., Prasad, K., Lemos, J. R. N., Arevalo, G., & Hirani, K. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26052320 · Cited by 185
“Beyond their metabolic effects, emerging evidence suggests that GLP-1R agonists may exert anti-inflammatory properties [345–347].”
Metadata
- Authors
- Mehdi, S. F., Pusapati, S., Anwar, M. S., Lohana, D., Kumar, P., Nandula, S. A., Nawaz, F. K., Tracey, K., Yang, H., LeRoith, D., Brownstein, M. J., & Roth, J.
- Affiliations
- Northwell Health (US)
- Icahn School of Medicine at Mount Sinai (US)
- Azevan Pharmaceuticals (United States) (US)
- Corresponding author
- Roth, Jesse
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2023-05-17
- Volume
- 14
- Pages
- 1148209-1148209
- ISSN
- 1664-3224 (ISSN-L)
- PMC
- PMC10230051
- OpenAlex
- W4377041419
- Cited by
- 317
- References
- 208
- Citations by year
- 2026: 107 · 2025: 138 · 2024: 61 · 2023: 10
- FWCI
- 11.40
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Immunology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Feinstein Institutes for Medical Research
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Keywords
- glucagon-like peptide-1, anti-inflammatory peptides, inflammation, sepsis, inflammatory cytokines, type 2 diabetes, metabolic syndrome, hyperglycemia, HbA1c, apoptosis, cardioprotection, neuroprotection, adjuvant therapy
- MeSH terms
- Anti-Inflammatory Agents, Diabetes Mellitus, Type 2, Humans, Inflammation, Peptides, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.